DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Blanke CD, Demetri GD, von Mehren M et al.
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
J Clin Oncol 2008;
26: 620-625
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.